Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 3/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 3/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 4/20 | 0.33 |
| ▸ | HTR2C | P28335 | 4/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24317709 | 0.85 | PGR (0.36) | PGRSLC6A2HTR2AHTR2CNCF1 | |
| SCHEMBL24317707 | 0.83 | MEN1 (0.37) | DRD2DRD3 | |
| SCHEMBL24316243 | 0.81 | DRD2 (0.36) | PGRDRD2DRD3 | |
| SCHEMBL24316251 | 0.81 | DRD2 (0.36) | DRD2DRD3 | |
| SCHEMBL690369 | 0.77 | DRD3 (0.42) | PGRDRD2DRD3 | |
| SCHEMBL24316248 | 0.76 | MEN1 (0.39) | DRD2DRD3 | |
| SCHEMBL13939978 | 0.76 | SIGMAR1 (0.41) | PGRSLC6A2DRD2DRD3HTR2A | |
| SCHEMBL24317706 | 0.75 | PGR (0.39) | PGRSLC6A2DRD3HTR2AHTR2C | |
| SCHEMBL13315451 | 0.73 | HTR2A (0.37) | SLC6A2DRD3HTR2AHTR2CNCF1 | |
| SCHEMBL24316249 | 0.72 | HTR2A (0.36) | PGRSLC6A2HTR2AHTR2CNCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2022081925-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-9585884-B2 | Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | PGR 2226/4885SLC6A2 2569/4885DRD2 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.